Uterine Fibroids in Senegal: Polymorphism of MED12 Gene and Correlation With Epidemiological Factors


Uterine Fibroids in Senegal: Polymorphism of MED12 Gene and Correlation With Epidemiological Factors


Kénémé Bineta1; Ciss Daouda2; Ka Sidy3; Mbaye Fatimata1; Dem Ahmadou3; Sembène Mbacké1,4
1Département de Biologie Animale, Faculté des Sciences et Techniques, Université Cheikh Anta Diop, BP 5505, Dakar, Sénégal.
2Service de Maternité et Gynécologie Obstétrique/Hôpital Général Grand Yoff.
3Institut Joliot Curie, Faculté de Médecine de Pharmacie et d’Odontologie, Université Cheikh Anta Diop, Dakar, Sénégal.
4Biologie des Populations Animales Sahélo-Soudaniennes, UMR 022, Institut de Recherche et de développement (IRD), Campus de Bel-Air, BP 1386, Dakar, CP 18524, Sénégal.


American Journal of Cancer Research and Reviews

Background: Mediator complex subunit 12 (MED12) is a part of the mediator complex, which is believed to regulate transcription. Our recent study showed that MED12 is mutated at high frequency and with different mutation frequencies in Senegalese women with uterine fibroids. However, the status of mutations has not been correlated to the epidemiological factors that are implicated in uterine fibroids.
Methods: This study aimed to analyze status of MED12 mutations in Senegalese population. MED12 was sequenced in tumoral tissues and blood samples of 54 Senegalese women with uterine fibroids. Clinical and pathological data were obtained from the patient’s records and other parameters were recorded. Mutation Surveyor software version 5.0.1, DnaSP version 5.10, MEGA version 7.0.26 and Arlequin version 3.5.1.3 were used to determine the level of mutations and genetics parameters. To estimate the genetic variation according to the epidemiological parameters, the index of genetic differentiation (Fst) and the genetic structure like analysis of molecular variance (AMOVA) were determined with Arlequin software version 3.5.1.3. The significance level (P-value) was 0.05.
Results: Our results showed that MED12 is mutated at 88.89% (48/54) only in tumor tissues. The variants frequencies were not similar to those found in the Finnish populations. The Chi2 test indicates a statistically significant difference for the variants c.130G>C, c.130G>A, c.131G>A and for the Intronic Variant Site (p <0.05). This variable expression of the MED12 gene is further confirmed by the amino acid frequency between blood and tumor tissue with a statistically significant difference for alanine, glutamic acid, lysine, methionine, threonine, valine, tryptophan and tyrosine (p <0.05). In addition, the selection test indicates that codon 44 is under positive selection (p=0.0243) in cases of uterine fibroids. Genetic diversity according to risk factors such as parity and diet was observed in uterine fibroids in Senegal (p <0.05).
Conclusion: Significant genetic diversity has been noted in uterine fibroids in Senegal. The codon 44 being under positive selection could be considered as a biomarker in uterine fibroids. Depending on the epidemiological parameters studied, parity and diet seem to be the risk factors most implicated in uterine fibroids in Senegal.


Keywords: UTERINE FIBROIDS, MED12, MUTATIONS STATUS, RISK FACTORS, SENEGAL

Free Full-text PDF


How to cite this article:
Kénémé Bineta; Ciss Daouda; Ka Sidy; Mbaye Fatimata; Dem Ahmadou; Sembène Mbacké. UTERINE FIBROIDS IN SENEGAL: POLYMORPHISM OF MED12 GENE AND CORRELATION WITH EPIDEMIOLOGICAL FACTORS. American Journal of Cancer Research and Reviews, 2018,2:4. DOI:10.28933/ajocrr-2017-12-2601


References:

1. Audebert A., (1990), Endométriose externe : histogénèse, étiologie et évolution naturelle, Rev Praticien; 40:1077-1081.
2. Baird D.D., Dunson D.B., Hill M.C., Cousins D., Schectman J.M., (2003). High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence, Am J Obstet Gynecol; 188:100–107.
3. Okolo S., (2008). Incidence, aetiology and epidemiology of uterine fibroids, Best Pract Res Clin Obstet Gynaecol; 22:571–588.
4. Schwartz S.M., Marshall L.M., Baird D.D., (2000). Epidemiologic contributions to understanding the etiology of uterine leiomyomata, Environ Heal Perspect; 108(5):821-827.
5. Flake G.P., Andersen J., Dixon D., (2003). Etiology and Pathogenesis of Uterine Leiomyomas: A Review, Environ Health Perspect ; 11(8):1037-1054.
6. Aissani B., Zhang K., Wiener H., (2015). Genetic determinants of uterine fibroid size in the Multiethnic NIEHS uterine fibroid study, Inter J Mol Epidemiol Genet; 6 (1):9-19.
7. Mäkinen N., Mehine M., Tolvanen J., Kaasinen E., Li Y., Lehtonen H.J., Gentile M., Yan J., Enge M., Taipale M., Aavikko M., Katainen R., Virolainen E., Böhling T., Koski T.A., Launonen V., Sjöberg J., Aaltonen L.A., (2011a). MED12, the Mediator Complex Subunit 12 Gene, Is Mutated at High Frequency in Uterine Leiomyomas, Science; 334:252-254.
8. Mäkinen N., Heinonen H.R., Moore S., Tomlinson I.P.M., van der Spuy Z.M., Aaltonen L.A., (2011b). MED12 exon 2 mutations are common in uterine leiomyomas from South African patients, Oncotarget; 2(12):966-969.
9. Bertsch E., Qiang W., Zhang Q., Espona-Fiedler M., Druschitz S., Liu Y., Mittal K., Kong B., Kurita T., Wei J.J., (2014). MED12 and HMGA2 mutations: Two independent genetic events in uterine leiomyoma and leiomyosarcoma, Mod Pathol; 27(8):1144–1153.
10. Kämpjärvi K., Järvinen T.M., Heikkinen T., Hoag K.W., Dufva1 O., Kontro M., Rassenti L., Hertlein E., Kipps T.J., Porkka K., Byrd J.C., de la Chapelle A., Vahteristo1 P., (2014). Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia, Oncotarget; 6(3):1884-1888.
11. Kénémé B., Mbaye F., Ka S., Diop B., Dem A., Sembène M. (2017). Mediator Complex Subunit 12 Gene Polymorphisms in Uterine Fibroids and Breast Fibroadenomas in Senegalese Women; Int. Biol. Biomed. J. Winter (3):8-16.
12. Hall T.A. (1999). BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser. 41:95-98.
13. Librado P., Rozas J., (2009). DnaSP version 5: a software for comprehensive analysis of DNA polymorphism data, Bioinformatics; 25:1451-1452.
14. Tamura K., Stecher G., Peterson D., Filipski A., and Kumar S., (2013). MEGA7: Molecular Evolutionary Genetics Analysis version 7. Mol Biol Evol; 30:2725-2729.
15. Excoffier L., Laval G., Schneider S., (2010). Arlequin version 3.1: An integrated software package for population genetics data analysis, Evol Bioinform Online; 1:45-50.
16. Je E.M., Kim M.R., Min K.O., Yoo N.J., Lee S.H., (2012). Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors. Int J Cancer; doi: 10.1002/ijc.27610.
17. De Graaff MA, Cleton-Jansen AM, Szuhai K, Bovee JV. (2013). Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity. Hum Pathol; 44(8):1597–604.
18. Barbieri C.E., Baca S.C., Lawrence M.S. (2012). Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet; 44(6):685–9.
19. Barbieri C.E., Sboner A., Rubin M.A., Garraway L.A. (2013). Mutation in prostate tumours from Caucasian patients. J Pathol; 230:453–456.
20. Kang Y.K., Guermah M., Yuan C.X., Roeder R.G., (2002). The TRAP/Mediator coactivator complex interacts directly with estrogen receptors alpha and beta through the TRAP220 subunit and directly enhances estrogen receptor function in vitro, PNAS; 99(5):2642–2647.
21. Farber M., Conrad S., Heinrichs W.L., (1972). Estradiol binding by fibroid tumors and normal myometrum. Obstet Gynecol; 40:479-486.
22. Rosati P., Exacoustos C., Mancuso S., (1992). Longitudinal evaluation of uterine myoma growth during pregnancy: a sonographic study, J Ultrasound Med; 1(1):511-515.
23. Strobelt N., Ghidini A., Cavallone M., (1994). Natural history of uterine leiomyomas in pregnancy, J Ultrasound Med; 1(3):399-401.
24. Marsh E.E., Ekpo G.E., Cardozo E.R., Brocks M., Dune T., Cohen L.S. (2013). Racial differences in fibroid prevalence and ultrasound findings in asymptomatic young women (18-30): a pilot study. Fertil Steril.; 99:1951-1957.
25. Turunen M., Spaeth J.M., Keskitalo S., (2014). Uterine leiomyoma-linked MED12 mutations disrupt Mediator associated CDK activity, Cell Rep; 7(3):654–660.
26. Parazzini F., Vecchia C.L., Negri E., Cecchetti G., Fedele L. (1988). Epidemiologic characteristics of women with uterine fibroids: a casecontrol study. Obstet Gynecol; 72:853–857.
27. Marshall L.M., Spiegelman D., Goldman M.B., Manson J.E., Colditz G.A., Barbieri R.L., Stampfer M.J., Hunter D.J. (1998). A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril; 70:432–439.
28. Wise L.A., Laughlin-Tommaso S.K. (2016). Epidemiology of Uterine Fibroids – From Menarche to Menopause, Clin Obstet Gynecol; 59(1):2–24. doi:10.1097/GRF.0000000000000164.
29. Chiaffarino F, et al. (1999). Diet and uterine myomas. Obstet Gynecol; 94(3):395–398.